Alkem Laboratories Limited (ALKEM) share price
₹5087.50 on NSE as of 2026-09-11. -0.98% on the day. market cap ₹60,829 Cr. P/E 28.2. 52-week range ₹5087.50 to ₹5890.00. Healthcare.
Alkem Laboratories FY26: Record Profits, Semaglutide Sprint, Occlutech Bet
At a glance
Alkem closed FY26 with its highest annual net profit on record—₹2,302 crore, up 6.3% from ₹2,165 crore in FY25. Revenue climbed 13.5% to ₹14,712 crore. EBITDA crossed ₹3,000 crore for the first time, with margin expanding from 19.4% to 20.4%.
The domestic branded generics business grew 9.7%, slower than headline revenue, because of a transitional restructuring in trade generics (the lower-margin channel). Internationally, the business grew 22.5%, held back by the crore-heavy decision to bet EUR 99 million (~₹1,100 crore) on Occlutech, a Swiss heart-device maker. A semaglutide launch in March 2026 claimed 11% market share within weeks.
The tension: margin has finally broken north, the chronic therapy mix is shifting upward, but the company has just committed a year's operating cash flow to a non-pharma acquisition while defending against tax scrutiny and positioning for leadership transition.
The question: does a 21.2% ROCE justify a 26.4x P/E when the company is no longer purely pharmaceutical?
Introduction
Alkem is the fifth-largest pharmaceutical company in India by market share (4.1% as of 9M FY25), with the #1 position in anti-infectives and top-3 spots in GI, pain, and vitamins/minerals/nutrients. It has 17 brands exceeding ₹1 billion in annual sales, including three "mega brands" above ₹5 billion. The distribution network spans 12,500+ field force, 9 central warehouses, 75+ depots, and 8,400+ stockists—the second-largest network in the country.
In February 2026, Alkem announced a binding offer to acquire 51–55% of Occlutech Holding AG, a Switzerland-based structural heart device company, for EUR 180.7 million (valued at ~₹1,952 crore equity). The transaction is expected to close within 45–60 days from the concall (early June 2026), funded entirely from cash on hand.
In March 2026, CEO Dr. Vikas Gupta resigned; his tenure closes on 30 June 2026 to allow a transition. The board is conducting a search using "top 3 global head-hunters."
On 2 June 2026, Alkem launched semaglutide pre-filled syringes in a single-shot weekly format at ₹350 after DCGI approval, priced 80% below the innovator. Within weeks, market share in the GLP-1 segment climbed to 11% unit share per IQVIA, positioning it as a material growth vector for FY27.
Business model
Alkem manufactures and sells branded and generic pharmaceuticals domestically, exports generics and biosimilars internationally, and operates contract manufacturing for biologics. The three segments are domestic (70% of revenue), international (30%), and emerging non-pharma (Occlutech, Enzene, MedTech—currently immaterial).
**Domestic: Acute Dominance, Chronic Acceleration**
The domestic business derives over 80% of revenue from acute therapies: anti-infectives (rank 1), pain (rank 3), and GI (rank 3). These categories are slower-growing and price-controlled. Chronic therapies—anti-diabetes, cardiology, neurology, respiratory, dermatology—now contribute close to 22% of branded generics, up 1% annually over four years.
Semaglutide enters this chronic ramp as a high-ticket new product. Management flagged it as "one of the biggest priorities" for FY27. The launch reached 11% market share in unit sales within three weeks, suggesting either effective market access or meaningful unmet demand or both.
The trade generics channel (below-brand generics sold through drugstore chains) contributed softer growth at 4.3% in FY26, a deliberate de-prioritization to lock down receivables and margin. This carveout as a separate entity means the reported number masks underlying profitability.
**International: Generic Focus, Biosimilar Constraints**
Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Alkem Laboratories Limited.
Companies in the same industry as Alkem Laboratories Limited
Pharmaceuticals